A Prospective, Open-Label, Multicenter Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping
Phase of Trial: Phase II
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Tc 99m tilmanocept (Primary)
- Indications Malignant melanoma; Rhabdomyosarcoma; Solid tumours
- Focus Diagnostic use
- Sponsors Cardinal Health; Navidea Biopharmaceuticals
- 21 Sep 2017 Planned End Date changed from 1 Sep 2017 to 1 Jun 2021.
- 21 Sep 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Jun 2021.
- 27 Jun 2017 Status changed from active, no longer recruiting to recruiting.